|Articles|November 17, 0001
B&L buys Pharmos piece; deal could hit $49 million
B&L buys Pharmos piece; deal could hit $49 millionRochester, NY-Bausch & Lomb has acquired the rights to theloteprednol etabonate ophthalmic business of Pharmos Corp. for a price thatmight reach $49 million.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Last year in glaucoma at EnVision Summit 2025
4
NeuroOp Guru: Understanding optic disc cupping after optic neuritis
5
























